AstraZeneca Investor Day Presentation Deck

100% Percentage of Patients Enhertu: extending clinical benefit to other cancers 80% 60% 40% 20% 0% No. at Risk: 23 Phase II DESTINY-Lung01 Robust and durable anti-cancer activity in patients with previously treated HER2m NSCLC Overall Survival ++ Median OS: 17.8 months (95% CI, 13.8-22.1) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Months 91 89 88 86 82 77 75 75 70 68 65 58 51 46 36 29 25 22 19 19 17 15 14 13 13 10 7 5 Median PFS follow-up for T-DXd was 15.5 months (range, 15.1-16.1) and for T-DM1 was 13.9 months (range, 11.8-15.1) Dashed lines indicate the 95% CI. Of 91 patients, 47 had died by the cutoff date. Data for 44 patients were censored as indicated by tick marks; patients were censored if they discounted treatment. 3 1 0 Best % Change in Sum of Diameters from Baseline 60- 40- 20+ -20- -40- -60- -80- -100- Phase II DESTINY-Gastric02 Efficacy results demonstrate clinically meaningful and durable responses Best Percentage Change of Tumour Size from Baseline Confirmed ORR: 38% (95% CI, 27.3-49.6) Subjects T-DXd 6.4 mg/kg (N = 79) ¹ 3

View entire presentation